Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pain, Postoperative 3 Prostatic Neoplasms 2 Pain 2 Leiomyoma 2 Hot Flashes 2 Breast Neoplasms 2 Uterine Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Malignant Neoplasms of Female Genital Organs 1 Lung Neoplasms 1 Ileus 1 Agnosia 1

Interventions

Gemcitabine 100 130-nm albumin-bound paclitaxel 34 Oxaliplatin 28 Capecitabine 27 Fluorouracil 25 Albumin-Bound Paclitaxel 23 Leucovorin 19 Irinotecan 18 Erlotinib Hydrochloride 14 Cyclophosphamide 12 Radiosurgery 11 pembrolizumab 10 Radiotherapy 10 Nivolumab 10 Bevacizumab 10 Surgical Procedures, Operative 9 avelumab 7 Docetaxel 7 Taxes 6 Cisplatin 6 ruxolitinib 5 folfirinox 5 Specimen Handling 5 Paclitaxel 5 Everolimus 5 Cetuximab 5 ALT-803 5 trametinib 4 spartalizumab 4 fludarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Pancreatic Neoplasms × Bupivacaine × Clear all

NCT02682082 2020-05-14

EUS-CPN

Centre hospitalier de l'Université de Montréal (CHUM)

Phase NA Terminated

Gastrointestinal

Agnosia, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡